Melanoma trials in Romania

In Romania 8 Also abroad 579

8 of 8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
Where
Bucharest, Cluj-Napoca, Craiova, Timisoara, Timișoara
Age
18 years and over
People
89 worldwide
Run by
H e x a l AG
See details and how to join2025-521919-39-00
Phase 1Taking people
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Where
Bucharest, Cluj-Napoca, Craiova
Age
18 years and over
People
120 worldwide
Run by
Biocon Biologics UK PLC
See details and how to joinNCT07476326 · EU 2025-525158-20-00
Phase 3Taking people
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Where
Craiova
Age
18 years and over
People
632 worldwide
Run by
mAbxience Research S.L.
See details and how to joinNCT07221734
Phase 1Taking people
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Where
Bucharest, Cluj-Napoca, Craiova
Age
18 years and over
People
120 worldwide
Run by
Alvotech Swiss AG
See details and how to joinNCT07475572 · EU 2025-525093-11-00
Phase 3Taking people
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
Where
Craiova
Age
18 years and over
People
119 worldwide
Run by
Mabxience Research S.L.
See details and how to join2025-521562-95-00
Phase 1Active, not recruiting
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Where
Bucharest, Cluj-Napoca, Craiova
Age
18 years and over
People
83 worldwide
Run by
Celltrion Inc.
See details and how to join2023-510017-26-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Cluj-Napoca, Craiova, Iași
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314
Phase 1Taking people
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
Where
Bucharest, Cluj-Napoca, Craiova
Age
18 years and over
People
34 worldwide
Run by
Intas Pharmaceuticals Limited
See details and how to join2025-522307-14-00